Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis

Cost-Effectiveness of Different Durations of Dual-Antiplatelet Use After Percutaneous Coronary Intervention

(2018) Yaron Arbel et al.   CANADIAN JOURNAL OF CARDIOLOGY

6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial

(2018) Joo-Yong Hahn et al.   LANCET

Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy

(2018) Byoung-Kwon Lee et al.   EuroIntervention

A3825 Effectiveness and implications of six-month dual antiplatelet therapy following implanting drug-eluting stents

(2018) Shanghelin Yin et al.   JOURNAL OF HYPERTENSION

Optimal duration of DAPT after second-generation drug-eluting stent in acute coronary syndrome

(2018) Ji-Yong Jang et al.   PLoS One

Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial

(2018) Elvin Kedhi et al.   BMJ-British Medical Journal

Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients

(2017) Tullio Palmerini et al.   EUROPEAN HEART JOURNAL

Impact of design of coronary stents and length of dual antiplatelet therapies on ischaemic and bleeding events: a network meta-analysis of 64 randomized controlled trials and 102 735 patients

(2017) Fabrizio D’Ascenzo et al.   EUROPEAN HEART JOURNAL

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS

(2017) Marco Valgimigli et al.   EUROPEAN HEART JOURNAL

The optimal discontinuation of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention with drug-eluting stents: A meta-analysis of randomized trials

(2017) Wei Wang et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin

(2017) Romain Didier et al.   JACC-Cardiovascular Interventions

Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy

(2017) Raffaele Piccolo et al.   JACC-Cardiovascular Interventions

Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation

(2017) Masato Nakamura et al.   JACC-Cardiovascular Interventions

Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting

(2017) Tullio Palmerini et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015

(2017) Gregory A. Roth et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials

(2017) Francesco Costa et al.   LANCET

Single or dual antiplatelet therapy after PCI

(2017) Yosuke Miyazaki et al.   Nature Reviews Cardiology

Multivariate and network meta-analysis of multiple outcomes and multiple treatments: rationale, concepts, and examples

(2017) Richard D Riley et al.   BMJ-British Medical Journal

Multivariate and network meta-analysis of multiple outcomes and multiple treatments: rationale, concepts, and examples

(2017) Richard D Riley et al.   BMJ-British Medical Journal

Short-versus long-term Dual Antiplatelet therapy after drug-eluting stent implantation in women versus men: A sex-specific patient-level pooled-analysis of six randomized trials

(2016) Fadi J. Sawaya et al.   CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS

Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

(2016)   CIRCULATION

Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent

(2016) Yaling Han et al.   Circulation-Cardiovascular Interventions

Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: conceptual evolution based on emerging evidence

(2016) Tullio Palmerini et al.   EUROPEAN HEART JOURNAL

Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents

(2016) James B. Hermiller et al.   JACC-Cardiovascular Interventions

6-Month Versus 12-Month Dual-Antiplatelet Therapy Following Long Everolimus-Eluting Stent Implantation

(2016) Sung-Jin Hong et al.   JACC-Cardiovascular Interventions

Stent Thrombosis With Drug-Eluting Stents and Bioresorbable Scaffolds

(2016) Si-Hyuck Kang et al.   JACC-Cardiovascular Interventions

2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease

(2016) Glenn N. Levine et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials

(2016) Giuseppe Gargiulo et al.   BMJ-British Medical Journal

Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials

(2016) Giuseppe Gargiulo et al.   BMJ-British Medical Journal

Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis

(2016) Raphaela Lohaus et al.   Scientific Reports

Longer- Versus Shorter-Duration Dual-Antiplatelet Therapy After Drug-Eluting Stent Placement

(2015) Frederick A. Spencer et al.   ANNALS OF INTERNAL MEDICINE

The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations

(2015) Brian Hutton et al.   ANNALS OF INTERNAL MEDICINE

Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial

(2015) Gérard Helft et al.   EUROPEAN HEART JOURNAL

Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial

(2015) F. Costa et al.   EUROPEAN HEART JOURNAL

ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting

(2015) S. Schulz-Schupke et al.   EUROPEAN HEART JOURNAL

Short- Versus Long-Term Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation

(2015) Tullio Palmerini et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction

(2015) Robert W. Yeh et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Long-Term Safety of Drug-Eluting and Bare-Metal Stents

(2015) Tullio Palmerini et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis

(2015) Sammy Elmariah et al.   LANCET

Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials

(2015) Tullio Palmerini et al.   LANCET

Epley and Semont maneuvers for posterior canal benign paroxysmal positional vertigo: A network meta-analysis

(2015) Yun Liu et al.   LARYNGOSCOPE

Switching P2Y12-receptor inhibitors in patients with coronary artery disease

(2015) Fabiana Rollini et al.   Nature Reviews Cardiology

Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis

(2015) Gert van Valkenhoef et al.   Research Synthesis Methods

Comparison of Outcomes After Percutaneous Coronary Intervention Among Different Coronary Subsets (Stable and Unstable Angina Pectoris and ST-Segment and Non-ST-Segment Myocardial Infarction)

(2014) Joshua P. Loh et al.   AMERICAN JOURNAL OF CARDIOLOGY

Systematic reviews and meta-analyses of randomized trials: principles and pitfalls

(2014) Bruno R. da Costa et al.   EUROPEAN HEART JOURNAL

Second-Generation Drug-Eluting Stent Implantation Followed by 6- Versus 12-Month Dual Antiplatelet Therapy

(2014) Antonio Colombo et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial

(2014) Jean-Philippe Collet et al.   LANCET

Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents

(2014) Laura Mauri et al.   NEW ENGLAND JOURNAL OF MEDICINE

Evaluating the Quality of Evidence from a Network Meta-Analysis

(2014) Georgia Salanti et al.   PLoS One

A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis

(2014) M. A. Puhan et al.   BMJ-British Medical Journal

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2013) David Moher   ANNALS OF INTERNAL MEDICINE

Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation

(2013) Cheol Whan Lee et al.   CIRCULATION

Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY)

(2013) M. Valgimigli et al.   EUROPEAN HEART JOURNAL

Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents

(2013) Fausto Feres   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study

(2013) Roxana Mehran et al.   LANCET

Graphical Tools for Network Meta-Analysis in STATA

(2013) Anna Chaimani et al.   PLoS One

Demystifying trial networks and network meta-analysis

(2013) E. J. Mills et al.   BMJ-British Medical Journal

Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting

(2012) Marco Valgimigli et al.   CIRCULATION

A New Strategy for Discontinuation of Dual Antiplatelet Therapy

(2012) Byeong-Keuk Kim et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents

(2011) Hyeon-Cheol Gwon et al.   CIRCULATION

Duration of Dual Antiplatelet Therapy after Implantation of Drug-Eluting Stents

(2010) Seung-Jung Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Risk of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Bare-Metal and Drug-Eluting Stents

(2009) Neville Kukreja et al.   JACC-Cardiovascular Interventions